TY
Tyra Biosciences, Inc.
TYRA · NASDAQ
$25.73 +4.55% (+$1.12)
1M -1.38%
Market Cap $1.54B
P/E Ratio -
Div. Yield -
ROE 46.39%
Bulios Fair Price
$19.05
26.0% downside
Current Price
$25.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TYRA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
46 /100
Fair P/B 4.34x
P/E N/A
EV/EBITDA N/A
Growth
26 /100
Declining Book val. growth 0.17%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 44.67%
ROE 46.39%
Asset turnover 0.00x
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 14.91x
Int. coverage N/A
Stability
71 /100
Stable Beta 0.73x
EPS volatility 22.64%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TYRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Todd Harris
Employees
87
Headquarters
Carlsbad
Upcoming events
04 NOV
Earnings
Upcoming earnings report